You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Sodium-glucose cotransporter-2 inhibitor

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
Aug 19, 2022

Called FLAMINgO to Learn More About Treatment Combination of

Active, not recruiting
  • Chronic Kidney Disease
  • Type 2 Diabetes
  • Finerenone (Kerendia, BAY94-8862)
  • Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
  • Whippany, New Jersey
    Bayer
Jan 19, 2023

Type2 Diabetes, Heart Failure With Preserved Ejection Fraction Trial in San Antonio (Empagliflozin 25 MG, Placebo)

Recruiting
  • Type2 Diabetes
  • Heart Failure With Preserved Ejection Fraction
  • Empagliflozin 25 MG
  • Placebo
  • San Antonio, Texas
  • +1 more
Jan 21, 2023

Chronic Kidney Diseases, Diabetes, PreDiabetes Trial in Vienna (Therapeutic carbohydrate restriction combined with an

Recruiting
  • Chronic Kidney Diseases
  • +3 more
  • Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor
  • Vienna, Austria
    6th Medical Department with Nephrology and Dialysis, Clinik Otta
Oct 16, 2023

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,

Not yet recruiting
  • Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
  • (no location specified)
Jan 22, 2023

Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas Trial in Saint Louis (Dapagliflozin, BIOSENSE meters)

Completed
Has Results
  • Pancreas Cancer
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 20, 2022

Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor Trial (Henagliflozin, Metformin)

Not yet recruiting
  • Obesity
  • +4 more
  • (no location specified)
Sep 27, 2023

Fabry Disease Trial (Dapagliflozin 10mg Tab, Placebo)

Not yet recruiting
  • Fabry Disease
  • Dapagliflozin 10mg Tab
  • Placebo
  • (no location specified)
Jan 23, 2023

Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies Trial (Other)

Not yet recruiting
  • Heart Failure
  • +3 more
  • (no location specified)
Oct 17, 2023

SGLT-2 Inhibitors in T2DM and Moderate to Severe Liver Fibrosis

Completed
  • Type2diabetes
    • New Delhi, Delhi, India
      Fortis CDOC Hospital
    Jul 14, 2023

    SGLT2-I in Diabetic AMI (SGLT2-I AMI PROTECT Study)

    Recruiting
    • Diabetes Mellitus
    • Acute Coronary Syndrome
      • Aalst, Belgium
      • +6 more
      Mar 2, 2022

      The Triglyceride/Glucose Index and SGLT-2 Inhibitors

      Recruiting
      • Metabolic Disease
      • Diabetes
      • SGLT-2 inhibitors
      • Samsun, İlkadım, Turkey
        Samsun Education and Research Hospital
      Jun 14, 2023

      Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)

      Recruiting
      • Heart Attack
      • Enlarged Heart
      • Minneapolis, Minnesota
        Minneapolis Heart Institute Foundation
      Aug 4, 2022

      Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)

      Recruiting
      • Heart Failure With Reduced Ejection Fraction
      • Chicago, Illinois
        University of Chicago
      Nov 11, 2022

      Type 1 Diabetes Trial in La Jolla (Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo)

      Completed
      • Type 1 Diabetes
      • Dapagliflozin 10 MG [Farxiga]
      • +2 more
      • La Jolla, California
        UC San Diego Altman Clinical & Translational Research Institute
      Jan 20, 2023

      Heart Failure Trial (Dapagliflozin, Placebo)

      Not yet recruiting
      • Heart Failure
      • (no location specified)
      Sep 19, 2022

      Heart Failure, Diabetes, Type 2 Trial in United States (Dapagliflozin 10 MG, Protocolized Diuretic Therapy)

      Recruiting
      • Heart Failure
      • Diabetes Mellitus, Type 2
      • Dapagliflozin 10 MG
      • Protocolized Diuretic Therapy
      • Jackson, Mississippi
      • +5 more
      Feb 1, 2022

      Diabetes, Diabetes, Type 1, Type1diabetes Trial in Chula Vista (YG1699, Dapagliflozin)

      Completed
      • Diabetes
      • +3 more
      • Chula Vista, California
        ProSciento, Inc
      Jul 27, 2022

      Sodium-glucose Cotransporter 2 Inhibitors and Risk of

      Completed
      • Type2 Diabetes
      • +5 more
      • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
      • Dipeptidyl peptidase-4 (DPP-4) inhibitors
      • Montreal, Quebec, Canada
        Lady Davis Institute for Medical Research, Jewish General Hospit
      Oct 1, 2020

      Sodium-glucose Cotransporter 2 Inhibitors Among Type 2 Diabetes

      Completed
      • Diabetes Mellitus, Type 2
      • +3 more
      • Sodium-glucose cotransporter 2 (SGLT2) inhibitors
      • +2 more
      • Montreal, Quebec, Canada
        Lady Davis Institute for Medical Research, Jewish General Hospit
      Aug 17, 2020

      Type2Diabetes, ASCVD Trial (SGLT2 inhibitor, GLP-1 receptor agonist, Combination drug)

      Recruiting
      • Type2Diabetes
      • ASCVD
      • SGLT2 inhibitor
      • +2 more
      • New York, New York
      • +1 more
      Dec 19, 2022

      SGLT2-I Use in DFUD: a Delphi Study

      Not yet recruiting
      • Diabetic Foot Ulcer
      • eDelphi method
      • (no location specified)
      Aug 14, 2023

      Chronic Kidney Diseases, Bone Diseases, Metabolic Trial in Mansoura (Dapagliflozin 10mg Tab, Placebo)

      Active, not recruiting
      • Chronic Kidney Diseases
      • Bone Diseases, Metabolic
      • Dapagliflozin 10mg Tab
      • Placebo
      • Mansoura, Aldakahliya, Egypt
        Urology and Nephrology center, Mansoura University
      Feb 16, 2023

      Non-alcoholic Fatty Liver Disease Trial in Kanazawa (Tofogliflozin, Glimepiride)

      Completed
      • Non-alcoholic Fatty Liver Disease
      • Kanazawa, Ishikawa, Japan
        Kanazawa University Graduate School of Medical Sciences
      Jun 30, 2021

      Acute Decompensated Heart Failure Trial in Chicago (SGLT2i, No SGLT2i)

      Not yet recruiting
      • Acute Decompensated Heart Failure
      • Chicago, Illinois
        University of Chicago
      Jun 10, 2022